首页 | 本学科首页   官方微博 | 高级检索  
     

错配修复基因hMLH1和hMSH2甲基化及突变与地方性砷中毒关系
引用本文:赵转地,张爱华,梁冰,黄晓欣. 错配修复基因hMLH1和hMSH2甲基化及突变与地方性砷中毒关系[J]. 环境与职业医学, 2010, 0(10): 618-621
作者姓名:赵转地  张爱华  梁冰  黄晓欣
作者单位:[1]贵阳医学院公共卫生学院,贵州贵阳550004 [2]深圳市宝安区松岗预防保健所,广东深圳518105 [3]中国人民解放军第44医院,贵州贵阳550009
基金项目:国家自然科学基金资助项目(编号:30760225 30960337); 贵州省重大专项基金(编号:黔科合重大专项字[2006]6016)(致谢:本课题得到解放军第四十四医院、贵州省卫生厅、黔西南州卫生局、兴仁县地方病防治办公室等单位以及潘雪莉、陈强等人的支持和帮助,在此一并致谢.)
摘    要:[目的]探讨错配修复基因hMLH1和hMSH2启动子区CpG岛甲基化及第12外显子(exon12)突变与燃煤污染型地方性砷中毒发生发展乃至癌变的关系。[方法]以砷中毒患者110例为病例组,按临床诊断分为轻、中、重度组;按皮肤病理诊断分为非癌变组和癌变组。采用甲基化特异性聚合酶链反应(MSP)法检测其中105例砷中毒患者和82例对照人群外周血中hMLH1和hMSH2基因启动子区的甲基化情况;采用聚合酶链反应-单链构象多态性分析(PCR-SSCP)检测110例砷中毒患者和110例对照人群外周血中hMLH1和hMSH2基因exon12突变情况。[结果]①轻、中、重度组砷中毒患者hMSH2基因甲基化阳性率分别为11.76%、16.28%和32.14%,均明显高于对照组,重度组亦明显高于轻度组(P〈0.05或P〈0.01);癌变组患者hMLH1和hMSH2基因甲基化阳性率分别为11.11%和27.78%,均明显高于对照组(P〈0.05);hMLH1和hMSH2基因甲基化阳性率均随临床病情和皮肤病变程度加重而增高(P〈0.05或P〈0.01)。②病例组和对照组均未发现hMLH1和hMSH2基因exon12突变。[结论]错配修复基因hMLH1和hMSH2启动子区甲基化是砷中毒发生发展乃至癌变的早期分子特征,亦可能是导致错配修复功能缺陷的主要方式之一。

关 键 词:砷中毒    错配修复基因hMLH1  错配修复基因hMSH2  甲基化  突变

A Study on Ralationship of the Methylation and Mutation of Mismatch Repair Gene hMLH1 and hMSH2 in Patients with Endemic Arsenism
ZHAO Zhuan-di,ZHANG Ai-hua,LIANG Bing,HUANG Xiao-xin. A Study on Ralationship of the Methylation and Mutation of Mismatch Repair Gene hMLH1 and hMSH2 in Patients with Endemic Arsenism[J]. Journal of Environmental & Occupational Medicine, 2010, 0(10): 618-621
Authors:ZHAO Zhuan-di  ZHANG Ai-hua  LIANG Bing  HUANG Xiao-xin
Affiliation:1.School of Public Health,Guiyang Medical University,Guiyang,Guizhou 550004,China;2. Songgang Disease Prevention and Health Care Institute of Baoan District,Shengzhen,Guangdong 518105, China;3.The 44th Hospital of People's Liberation Army,Guiyang,Guizhou 550009,China).
Abstract:[Objective] To explove the relationship of the promoter 5’CpG island methylation of mismatch repair gene hMLH1 and hMSH2 and the mutation of their exon12 with the effect of arsenism development cause by coal-burning,and also the process of canceration.[Methods] A total of 110 cases of arsenism patients were selected as case group,classified as mild, moderate and severe subgroups according to their clinical diagnosis,and also divided into non-cancerous and carcinoma subgroups according to the pathology of their skin lesions.Methylation status of the hMLH1 and hMSH2 promoter region were assayed by methylation-specific polymerase chain reaction(MSP)in peripheral blood of 105 arsenism patients and 82 normal controls.The mutations of hMLH1 and hMSH2 exon12 were analyzed by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP)in peripheral blood DNA of 110 arsenism patients and 110 normal controls.[Results] ①The positive rates of hMSH2 methylation were 11.76%,16.28%and 32.14%in mild,moderate and severe patients respectively,all significantly higher than those in controls,and the rate in severe patients were significantly higher than that in moderate.The positive rates of hMLH1 and hMSH2 were 11.11%and 27.78%in non-cancerous and carcinoma groups respectively,both significantly higher than that in controls.With the severity of clinical condition and skin lesions the positive rates of hMLH1 and hMSH2 methylation increased. ②There were no mutations of mismatch repair gene hMLH1and hMSH2 exon12 in patients and controls.[Conclusion] The promoter hypermethylation of the mismatch repair gene hMLH1and hMSH2 is an early incident in the development of arsenism and in the process of carcinogenesis,and it may be one of the main reasons leading to its defect or deactivation of gene function.
Keywords:arsenism  coal  mismatch repair gene hMLHl  mismatch repair gene hMSH2  methylation  mutation
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号